S.3021: Gluten in Medicine Disclosure Act of 2019

December 16, 2019

On December 11, 2019, Senator Richard Blumenthal [D-CT] introduced S.3021, to the Senate floor. This bill is meant to amend the Federal Food, Drug, and Cosmetic Act to require the label of a drug that is intended for human use and contains an ingredient that is derived directly or indirectly from a gluten-containing grain to identify each such ingredient, and for other purposes. It will also be known as the Gluten in Medicine Disclosure Act of 2019 and uses the same language as H.R. 2074, the bill Representative Tim Ryan [D-OH] introduced to the House in April.

If passed, the bill would amend the Federal Food, Drug, and Cosmetic Act to require gluten be labeled in all medications.

Read the bill.


How You Can Help

Beyond Celiac encourages you to support the Gluten in Medicine Disclosure Act of 2019 by contacting your representatives and encouraging them to cosponsor this bill. A list of those currently cosponsoring this bill can be found here.

1. Call, write, email, or send a message to your Senators and Congressional reps urging them to cosponsor this and the corresponding House bill. Include a personal story.

2. Set up district meetings as Senators are back home during recesses.

3. Attend local events and talk to their your Senators and their staff at the events urging them to cosponsor.

Contact Your Representatives

Download a sample letter for your congressperson written by the staff at Beyond Celiac:


In November 2019, Beyond Celiac Director of Administration, Nancy Ginter, in Washington, D.C. to lobby senators and representatives about H.R. 2074, the Gluten in Medicine Disclosure Act of 2019. Nancy (left) is pictured here with Leah Steckler, MD, Healthcare Fellow in the office of Senator Pat Toomey of Pennsylvania.
OUR PARTNERS